Kymera Therapeutics. has been granted a patent for compounds and methods aimed at the targeted degradation of proteins. This invention specifically addresses the treatment of disorders associated with target proteins, utilizing a defined compound formula for administration to patients. GlobalData’s report on Kymera Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Kymera Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Kymera Therapeutics's grant share as of June 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12006329B2 outlines a method for treating various protein-mediated disorders, diseases, or conditions in patients through the administration of a specific compound identified as Formula II-b'?. The claims detail a wide range of disorders that can be targeted by this method, including numerous types of cancers such as squamous-cell carcinoma, basal cell carcinoma, and various leukemias and lymphomas. The comprehensive list of conditions also encompasses sarcomas and other malignancies, indicating the potential broad applicability of the treatment across different cancer types.
Further claims specify the structural components of the compound, including variations in substituents (R1 and R2) and the nature of the linking groups (L2) and rings (Ring B) that can be utilized in the compound's formulation. These components can include a variety of chemical groups such as halogens, aliphatic chains, and heterocyclic structures, allowing for significant flexibility in the design of the therapeutic agent. The patent emphasizes the versatility of the compound in targeting a wide array of malignancies, suggesting its potential as a significant therapeutic option in oncology.
To know more about GlobalData’s detailed insights on Kymera Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
